The global Cell-Free DNA (cfDNA) Testing Market is forecasted to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research.
The global Cell-Free DNA (cfDNA) Testing Market is forecasted to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research. The increasing prevalence of chronic diseases and cancer is a key factor driving the growth of this market. In addition, the development of non-invasive prenatal diagnosis (NIPD) is another major factor expected to fuel market growth over the forecast period.
Cell-free DNA testing is a type of molecular diagnostic test that detects the presence of cell-free DNA in the blood. This test can be used for a variety of purposes, including the detection of genetic abnormalities, the diagnosis of cancer, and the identification of infectious diseases.
Technological advancements and growth in the non-invasive prenatal testing (NIPT) market are the key drivers of the cell-free DNA testing market. In recent years, there has been a shift from invasive to non-invasive methods of prenatal diagnosis, which is expected to fuel the growth of the cell-free DNA testing market during the forecast period.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/156
Additionally, the cell-free DNA testing market is expected to be driven by the increasing incidence of genetic disorders and chromosomal abnormalities. According to the National Institutes of Health, in the United States, around 6,000 babies are born with a birth defect each year. Also, Down syndrome is the most common chromosome abnormality, affecting one in every 700 babies born in the United States.
Some Key Highlights from the Report
- In August 2019, Agilent Technologies Inc. acquired Exosome Diagnostics, Inc., a leading company in the cell-free DNA testing market. The acquisition will help Agilent to expand its portfolio in the field of oncology and other diseases.
- Cell-free DNA (cfDNA) is circulating DNA that is not associated with cells. It can be isolated from plasma or serum and used for a variety of applications, including DNA sequencing, diagnosis, and prognosis. cfDNA testing is a relatively new technology that is being increasingly used in the diagnosis of cancer and other diseases.
- Cancer is one of the leading causes of death worldwide. According to the World Health Organization (WHO), cancer was responsible for an estimated 9.6 million deaths in 2018. Early detection of cancer is crucial for successful treatment and survival. cfDNA testing is a promising tool for early detection of cancer, as it can detect small amounts of DNA that are shed from tumors into the bloodstream.
- cfDNA testing is also being studied for its potential to screen for other diseases, such as cardiovascular disease, infectious diseases, and prenatal conditions. However, the use of cfDNA testing for these indications is still in the early stages of research and is not yet approved by the US Food and Drug Administration (FDA).
- The MPSS technology segment is expected to grow at a CAGR of 18.0% during the forecast period due to its increasing adoption in the cell-free DNA testing market. MPSS is a novel sequencing technology used to study genome variation and function. It has been used to sequence bacterial, plant, and mammalian genomes. MPSS can be used to sequence genomes of any size and complexity. The technology is based on the principle of massively parallel sequencing, which allows for the simultaneous sequencing of millions of DNA molecules. MPSS has several advantages over other sequencing technologies, such as its ability to sequence very large genomes, high accuracy, and low cost. Due to these advantages, MPSS is expected to grow at a higher CAGR during the forecast period.
- The gynecology segment is anticipated to lead the market during the forecasted period due to the rising need for early and accurate diagnosis of genetic diseases such as Down syndrome, Edwards syndrome, Patau syndrome, etc. in pregnant women. Cell-free DNA tests can also help to distinguish between fetal aneuploidy and maternal malignancy. Apart from this, the oncology segment is projected to grow at a rapid pace during the forecast period due to the rising prevalence of cancer and increasing demand for early diagnosis of the disease.
- The North America region is expected to dominate the global cell-free DNA testing market throughout the forecast period. This is attributed to the presence of a large number of key players in the region and the increasing adoption of cell-free DNA tests in the United States.
- Key participants include Sequenom, Inc., Quest Diagnostics, Illumina Inc., Agilent Technologies, Inc., Guardant Health, Inc., Biodesix, Inc., Allenex AB, Roche Holdings AG, Biocept, Inc., and CareDx, Inc., among others.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/cell-free-dna-market
Emergen Research has segmented the global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:
Type Outlook (Revenue, USD Billion; 2017-2027)
- Cell-free fetal DNA (NIPT)
- Circulating tumor DNA
- Donor-derived cell-free DNA
Technology Outlook (Revenue, USD Billion; 2017-2027)
- MPSS
- t-MPS
- SNP
- Others
Application Outlook (Revenue, USD Billion; 2017-2027)
- Transplantation
- Gynecology
- Oncology
Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- MEA
- Saudi Arabia
- UAE
- Rest of MEA
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/156
Explore More Reports Emergen Research:
Autonomous Delivery Vehicle Market
Advanced Driver Assistance Systems Market
anti-money laundering software market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-cell-free-dna-market